• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Vilya

  • November 25, 2022
  • New Biotech Startups

Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class of medicines that combine the advantages of traditional small-molecule drugs and larger protein therapeutics.

In a paper published in Cell in September 2022 titled “Accurate de novo design of membrane-traversing macrocycles” scientists at IPD describe one element of the research behind Vilya’s foundational technology, which uses computational methods to robustly design membrane-permeable and orally bioavailable peptides with high structural accuracy.

The drug design breakthrough may lead to new medications for a wide variety of health disorders, including cancer, infection, and inflammation. Vilya intends to leverage its platform to focus on previously difficult-to-drug therapeutic targets.

Vilya was co-founded by a team of scientists from the IPD including David Baker, Ph.D. The company was funded $50 million in a Series A round led by ARCH Venture Partners in 2022.


Subscribe for alerts on new companies featured on Startups.Bio


April 21, 2023T-Therapeutics
T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases. Founded in 2022, the company is based on technology from Professor Allan …
March 26, 2023Empyrean Neuroscience
Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting and engineering of the fungal …
March 3, 2023EnPlusOne Biosciences
EnPlusOne Biosciences aims to bring a versatile, sustainable, and scalable RNA synthesis technology to market to unlock development of new RNA drugs, vaccines, and gene-editing therapies. The company's advanced-stage technology …
January 25, 2023MxT Biotech
MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporatorâ„¢ is a non-viral microfluidic platform …

View all recently featured startups


Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.